Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ANX105 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ANX105 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ANX105 | BIOLOGICAL | Participants will receive single-ascending doses of ANX105 administered by IV infusion. |
| Placebo | DRUG | Participants will receive matching placebo administered by IV infusion. |
Key Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests. * Have been fully vaccinated with SARS-CoV-2 vaccination according to local guidelines within 14 days prior to Day -1. * Document...
ANX105 is an investigational monoclonal antibody being developed by Annexon, Inc. It is currently in Phase 1 clinical development. The drug has been studied in a single ascending dose trial in healthy volunteers, with the trial completed.
ANX105 is being studied for use in healthy volunteers as part of early clinical development. The completed Phase 1 trial evaluated single ascending doses of the drug in healthy participants to assess safety and tolerability.
ANX105 is being developed by Annexon, Inc., a biopharmaceutical company. The company's stock is listed under the ticker symbol ANNX on the stock market.
ANX105 is in Phase 1 clinical development. The Phase 1 trial, which was a single ascending dose study, has been completed. The drug is still in the investigational stage and has not been approved for any use.
ANX105 has one completed clinical trial, identified as NCT05288881. This was a Phase 1, single ascending dose study conducted in the Netherlands with 23 healthy participants. The trial was randomized, double-blind, and placebo-controlled.
ANX105 is not known to have alternative names. It is a distinct investigational monoclonal antibody being developed by Annexon, Inc. for potential therapeutic use.